BMY (Bristol-Myers Squibb Company) — AI Stock Analysis & Recommendation

Research of September 15, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate BMY a HOLD. The latest price is $60.57.

The research plan

• Entry: $63.97
• Time horizon: N/A

Mandatory rules prevent a trade at this time.

Why

Mandatory rules prevent a trade at this time. Catalysts to watch: BMY trades at a significant discount (forward P/E 9.72x vs. industry 18.70x), indicating undervaluation; Management's raised FY26 guidance and a robust 'Growth Portfolio' are driving organic revenue expansion; Generally positive news sentiment driven by promising clinical trial data and recent FDA approvals. Key risks: The stock is currently trading within 0.38% of its nearest resistance level ($63.97), making a favorable entry impossible; BMY faces significant revenue declines from key blockbuster drugs due to looming patent expirations; The success of BMY's strategic transition is highly dependent on its R&D pipeline delivering new drugs and navigating regulatory risks.

What could push BMY higher

• BMY trades at a significant discount (forward P/E 9.72x vs. industry 18.70x), indicating undervaluation.
• Management's raised FY26 guidance and a robust 'Growth Portfolio' are driving organic revenue expansion.
• Generally positive news sentiment driven by promising clinical trial data and recent FDA approvals.

Key risks for BMY

• The stock is currently trading within 0.38% of its nearest resistance level ($63.97), making a favorable entry impossible.
• BMY faces significant revenue declines from key blockbuster drugs due to looming patent expirations.
• The success of BMY's strategic transition is highly dependent on its R&D pipeline delivering new drugs and navigating regulatory risks.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Bristol Myers Squibb appears fundamentally undervalued, trading at a significant discount to peers despite strong profitability, robust free cash flow, and a proactive strategy to address upcoming patent expirations through M&A and a growing product pipeline. While patent cliffs pose a material long-term risk, the current valuation, strong financial health, and management's positive guidance suggest a compelling...

• BMY trades at a significant discount (forward P/E 9.72x vs. industry 18.70x), indicating undervaluation despite strong profitability and FCF generation.
• Management's raised FY26 guidance and a robust 'Growth Portfolio' are driving organic revenue expansion and offsetting declines in legacy products.
• Robust free cash flow ($11.44 billion TTM) and healthy liquidity provide financial stability, with debt manageable despite a high D/E ratio.

Technical team: Bearish

The analysis presents conflicting signals, with a strong bearish Double Top pattern and breakdown below its neckline ($63.97) suggesting a trend reversal. While the prior trend was an uptrend with low-volume pullback, and momentum indicators are deeply oversold, these bullish signals are likely short-term bounces within a broader bearish context. The price is currently below the critical neckline, confirming the...

• Primary uptrend, but currently neutral with price testing resistance at $63.97 after a pullback.
• Prior uptrend confirmed by accumulation; current pullback shows decreasing volume, suggesting weak selling pressure rather than strong distribution.
• Deeply oversold RSI and Stochastic suggest a strong potential for a short-term bounce, though MACD shows increasing bearish momentum.

Sentiment team: Bullish

Overall sentiment for BMY is moderately bullish, primarily driven by positive clinical trial data, recent FDA approvals, and strong financial performance, which are reflected in news and professional analyst views. However, significant concerns such as the looming patent cliff and institutional net selling temper the conviction. The stock's oversold technical condition, coupled with improving sentiment, suggests...

• Bristol Myers Squibb exhibits a generally positive news sentiment driven by promising clinical trial data, recent FDA approvals, strong financial performance, and increased analyst and institutional investor optimism, despite some broader market headwinds...
• Retail investor sentiment for BMY is mixed, with bullishness on Stocktwits and positive pipeline news tempered by low active discussion on Reddit and ongoing concerns about patent expirations
• Analyst sentiment is generally positive, driven by a 'Moderate Buy' consensus and strong oncology pipeline data, though significant institutional net selling and a looming patent cliff present notable headwinds

Risk team: High

BMY faces significant structural risks from impending patent cliffs and the critical need for successful R&D pipeline execution to offset anticipated revenue declines. This, combined with a history of deep price drawdowns and elevated debt, points to a high overall risk profile. A small position size and strict risk management are essential, despite the current oversold technical signal.

• Patent Cliffs and Portfolio Transition: BMY faces significant revenue declines from key blockbuster drugs due to patent expirations, requiring a successful and rapid transition to a new growth portfolio.
• R&D Pipeline Execution and Regulatory Risk: The success of BMY's strategic transition is highly dependent on its R&D pipeline delivering new drugs and securing timely regulatory approvals, an inherently high-risk process.
• Deep Historical Price Drawdown: The stock has experienced a maximum drawdown of over 51% in the last year, indicating significant historical downside potential and price volatility.

BMY at a glance

Market value	$125.9B
Price / earnings	13.5
Revenue growth (year over year)	3.1%
Profit margin	18.9%
Debt / equity	1.92

Every AI call on BMY since May 4, 2026, and what happened next (5 calls) →

Research of September 15, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.